Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 12/20 | 0.56 |
| ▸ | ESR1 | P03372 | 6/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | MIF | P14174 | 4/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL382897 | 1.00 | ESR2 (0.56) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL17327330 | 1.00 | ESR2 (0.56) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL10197496 | 0.88 | DGAT1 (0.47) | ESR2ESR1CYP3A4CYP2C9DGAT1 | |
| SCHEMBL16969312 | 0.87 | ESR2 (0.51) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL4673308 | 0.86 | DGAT1 (0.46) | ESR2ESR1CYP3A4CYP2C9DGAT1 | |
| SCHEMBL18763690 | 0.86 | DGAT1 (0.51) | DGAT1MIFALDH1A1LMNAMAPT | |
| SCHEMBL28817040 | 0.86 | IDO1 (0.56) | DGAT1MAPT | |
| SCHEMBL17327303 | 0.86 | DGAT1 (0.51) | DGAT1MIFALDH1A1LMNAMAPT | |
| SCHEMBL1399745 | 0.86 | DGAT1 (0.51) | ESR2ESR1CYP3A4CYP2C9DGAT1 | |
| SCHEMBL28102452 | 0.86 | DGAT1 (0.46) | ESR2ESR1CYP3A4CYP2C9DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10987322-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20170112785-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. | 2017-04-27 | — | — | US | disclosed |
| US-9321728-B2 | Beta-alanine derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical composition comprising same as active ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2016-04-26 | — | — | US | disclosed |
| US-9321728-B2 | Beta-alanine derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical composition comprising same as active ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2016-04-26 | — | — | US | disclosed |
| US-9321728-B2 | Beta-alanine derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical composition comprising same as active ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2016-04-26 | — | — | US | disclosed |
| US-20150329504-A1 | NOVEL BETA-ALANINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2015-11-19 | — | — | US | disclosed |
| US-20150329504-A1 | NOVEL BETA-ALANINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2015-11-19 | — | — | US | disclosed |
| US-20150329504-A1 | NOVEL BETA-ALANINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2015-11-19 | — | — | US | disclosed |
| EP-2842938-A1 | NOVEL BETA-ALANINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | Korea Research Institute of Chemical Technology (KR) | 2015-03-04 | — | — | EP | disclosed |
| EP-2842938-A1 | NOVEL BETA-ALANINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | Korea Research Institute of Chemical Technology (KR) | 2015-03-04 | — | — | EP | disclosed |
| CN-101466690-A | (trans-4- [ ({5- [ (3)) | ASTRAZENECA AB (SE) | 2009-06-24 | — | — | CN | disclosed |
| CN-101460492-A | Benzimidazoles and their use for the treatment of diabetes | ASTRAZENECA AB (SE) | 2009-06-17 | — | — | CN | disclosed |
| EP-2035417-A1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATEMNT OF DIABETES | AstraZeneca AB (SE) | 2009-03-18 | — | — | EP | disclosed |
| EP-2032546-A1 | OXAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY | Astra Zeneca AB (SE) | 2009-03-11 | — | — | EP | disclosed |
| WO-2008129319-A1 | SALTS OF OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | disclosed |
| WO-2007141517-A1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATEMNT OF DIABETES | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007141538-A1 | OXAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
| US-20070244096-A1 | Fused Bicyclic Nitrogen-Containing Heterocycles | JAPAN TOBACCO INC. (JP) | 2007-10-18 | — | — | US | disclosed |
| US-20070244096-A1 | Fused Bicyclic Nitrogen-Containing Heterocycles | JAPAN TOBACCO INC. (JP) | 2007-10-18 | — | — | US | disclosed |
| US-7244727-B2 | Fused bicyclic nitrogen-containing heterocycles | JAPAN TOBACCO INC. (JP) | 2007-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329504-A1 | NOVEL BETA-ALANINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | DGAT1, GOT1, ACAT2 | ESR2 4409/4885ESR1 4609/4885CYP3A4 1136/4885 |
| US-20170112785-A1 | IMMUNOREGULATORY AGENTS | IDO1, IDO2, INMT | ESR2 1493/4885ESR1 3892/4885CYP3A4 1482/4885 |
| US-10987322-B2 | Immunoregulatory agents | IDO1, IDO2, INMT | ESR2 1493/4885ESR1 3892/4885CYP3A4 1482/4885 |
| US-20070244096-A1 | Fused Bicyclic Nitrogen-Containing Heterocycles | PC, HCCS, MYC | ESR2 604/4885ESR1 2230/4885CYP3A4 2783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.